09:18 AM EST, 01/29/2025 (MT Newswires) -- Greenwich LifeSciences ( GLSI ) said Wednesday that the European Medicines Agency has approved its application to add 11 new sites in Spain, Germany, and Poland for a late-stage trial of GLSI-100 to prevent breast cancer recurrences.

The company said that with the latest approval, regulators have cleared the way for the activation of 110 to 115 sites in Europe.

Greenwich said it plans to file applications with the EMA to add 5 to 10 additional sites in Ireland, Romania, and potentially other European countries.